• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三氧化二砷联合化疗治疗复发/难治性多发性骨髓瘤的疗效和安全性的 Meta 分析和系统评价

Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

机构信息

Department of Hematology, General Hospital of Beijing Military Area of PLA, Beijing, People's Republic of China.

出版信息

Onco Targets Ther. 2014 Sep 10;7:1593-9. doi: 10.2147/OTT.S67165. eCollection 2014.

DOI:10.2147/OTT.S67165
PMID:25246802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4166211/
Abstract

Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate significant benefit for MM patients with improved survival, all MM patients still relapse. Arsenic trioxide (ATO) is the most active single agent in acute promyelocytic leukemia, the antitumor activity of which is partly dependent on the production of reactive oxygen species. Due to its multifaceted effects observed on MM cell lines and primary myeloma cells, Phase I/II trials have been conducted in heavily pretreated patients with relapsed or refractory MM. Therapy regimens varied dramatically as to the dosage of ATO and monotherapy versus combination therapy with other agents available for the treatment of MM. Although ATO-based combination treatment was well tolerated by most patients, most trials found that ATO has limited effects on MM patients. However, since small numbers of patients were randomized to different treatment arms, trials have not been statistically powered to determine the differences in progression-free survival and overall survival among the experimental arms. Therefore, large Phase III studies of ATO-based randomized controlled trials will be needed to establish whether ATO has any potential beneficial effects in the clinical setting.

摘要

多发性骨髓瘤(MM)是一种克隆性恶性肿瘤,其特征是骨髓中恶性浆细胞的增殖和单克隆免疫球蛋白的产生。尽管一些新批准的药物(沙利度胺、来那度胺和硼替佐米)显示出对改善 MM 患者生存的显著益处,但所有 MM 患者仍会复发。三氧化二砷(ATO)是急性早幼粒细胞白血病中最有效的单一药物,其抗肿瘤活性部分依赖于活性氧的产生。由于其对 MM 细胞系和原代骨髓瘤细胞的多方面作用,已在复发或难治性 MM 的大量预处理患者中进行了 I/II 期试验。ATO 的剂量以及单药治疗与其他可用于治疗 MM 的药物联合治疗的方案因试验而异。尽管基于 ATO 的联合治疗被大多数患者耐受良好,但大多数试验发现 ATO 对 MM 患者的作用有限。然而,由于不同治疗组的患者数量较少,试验没有统计学能力来确定实验组之间无进展生存期和总生存期的差异。因此,需要进行基于 ATO 的大型 III 期随机对照试验,以确定 ATO 在临床环境中是否具有任何潜在的有益效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dc8/4166211/30b1d2bfb49e/ott-7-1593Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dc8/4166211/4d1afab84688/ott-7-1593Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dc8/4166211/30b1d2bfb49e/ott-7-1593Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dc8/4166211/4d1afab84688/ott-7-1593Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dc8/4166211/30b1d2bfb49e/ott-7-1593Fig2.jpg

相似文献

1
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.三氧化二砷联合化疗治疗复发/难治性多发性骨髓瘤的疗效和安全性的 Meta 分析和系统评价
Onco Targets Ther. 2014 Sep 10;7:1593-9. doi: 10.2147/OTT.S67165. eCollection 2014.
2
The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.三氧化二砷治疗复发难治性多发性骨髓瘤的疗效:一项系统评价
Cancer Treat Rev. 2009 Aug;35(5):425-30. doi: 10.1016/j.ctrv.2009.04.007. Epub 2009 May 22.
3
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病:一项系统评价与荟萃分析
Zhong Xi Yi Jie He Xue Bao. 2009 Nov;7(11):1024-34. doi: 10.3736/jcim20091102.
4
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗:当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
5
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.三氧化二砷在骨髓瘤细胞中利用半胱天冬酶依赖性和非依赖性死亡途径。
Mol Cancer Ther. 2003 Nov;2(11):1155-64.
6
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.三氧化二砷治疗急性早幼粒细胞白血病:NICE 单技术评估的循证评价组视角。
Pharmacoeconomics. 2019 Jul;37(7):887-894. doi: 10.1007/s40273-018-0738-y.
7
Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.阿糖胞苷在全反式维甲酸和三氧化二砷联合治疗儿童急性早幼粒细胞白血病中的作用:一项随机对照试验。
BMC Cancer. 2018 Apr 3;18(1):374. doi: 10.1186/s12885-018-4280-2.
8
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.三氧化二砷在血液系统恶性肿瘤中的应用:一种古老药物的新发现
Curr Pharm Biotechnol. 2006 Dec;7(6):397-405. doi: 10.2174/138920106779116829.
9
Expanding the use of arsenic trioxide: leukemias and beyond.拓展三氧化二砷的应用:白血病及其他疾病
Semin Hematol. 2002 Apr;39(2 Suppl 1):22-6. doi: 10.1053/shem.2002.33611.
10
Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.难治性多发性骨髓瘤患者使用三氧化二砷:一项前瞻性、II期、单臂研究。
Acta Med Iran. 2011;49(8):504-8.

引用本文的文献

1
Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study.新诊断的多发性骨髓瘤患者中三氧化二砷-VTD方案与VRD方案相比的耐受性优势:一项前瞻性、开放标签研究。
Int J Med Sci. 2025 Apr 28;22(10):2373-2381. doi: 10.7150/ijms.110231. eCollection 2025.
2
Association between Arsenic Level, Gene Expression in Asian Population, and In Vitro Carcinogenic Bladder Tumor.砷水平与亚洲人群基因表达及体外膀胱癌致癌性的关联。
Oxid Med Cell Longev. 2022 Jan 7;2022:3459855. doi: 10.1155/2022/3459855. eCollection 2022.

本文引用的文献

1
New approaches to management of multiple myeloma.多发性骨髓瘤的治疗新方法。
Curr Treat Options Oncol. 2014 Jun;15(2):157-70. doi: 10.1007/s11864-014-0276-6.
2
The synergistic antitumor activity of arsenic trioxide and vitamin K2 in HL-60 cells involves increased ROS generation and regulation of the ROS-dependent MAPK signaling pathway.三氧化二砷与维生素K2在HL-60细胞中的协同抗肿瘤活性涉及活性氧生成增加以及对活性氧依赖性丝裂原活化蛋白激酶信号通路的调控。
Pharmazie. 2013 Oct;68(10):839-45.
3
Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide.
三氧化二砷诱导原发性样本中多发性骨髓瘤细胞的选择性凋亡。
Hematology. 2014 Sep;19(6):346-51. doi: 10.1179/1607845413Y.0000000134. Epub 2013 Nov 25.
4
Neuroprotective effect of resveratrol on arsenic trioxide-induced oxidative stress in feline brain.白藜芦醇对三氧化二砷诱导的猫脑氧化应激的神经保护作用。
Hum Exp Toxicol. 2014 Jul;33(7):737-47. doi: 10.1177/0960327113506235. Epub 2013 Oct 9.
5
Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.三氧化二砷抑制 Hedgehog 通路,该通路在急性早幼粒细胞白血病中异常激活。
Acta Haematol. 2013;130(4):260-7. doi: 10.1159/000351603. Epub 2013 Jul 17.
6
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.三氧化二砷(Trisenox)、抗坏血酸和硼替佐米(Velcade)联合治疗复发/难治性多发性骨髓瘤患者的 I 期研究。
Cancer Invest. 2013 Mar;31(3):172-6. doi: 10.3109/07357907.2012.756109. Epub 2013 Feb 13.
7
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.谷胱甘肽水平和凋亡调节剂的改变与多发性骨髓瘤获得三氧化二砷耐药性有关。
PLoS One. 2012;7(12):e52662. doi: 10.1371/journal.pone.0052662. Epub 2012 Dec 21.
8
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
9
Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.难治性多发性骨髓瘤患者使用三氧化二砷:一项前瞻性、II期、单臂研究。
Acta Med Iran. 2011;49(8):504-8.
10
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.硼替佐米、大剂量马法兰、三氧化二砷和抗坏血酸预处理方案的随机 2 期试验。
Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1.